Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 26;31(2):323–334. doi: 10.3904/kjim.2015.004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 The Korean Association of Internal Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — The effects of inhibition of renin angiotensin system and TLR on renal fibrosis at 7 days after UUO. (A) Masson’s trichrome (MT) staining and (B) TGF-β staining of (a) sham-operated, (b) UUO, (c) aliskiren-treated WT UUO, and (d) aliskiren-treated TLR2-KO UUO kidneys (×200). Ae and Be show quantification of the data in each panel. (Ab) MT-stained and (Bb) TGF-β stained areas were larger in UUO kidneys compared with sham-operated kidneys. Aliskiren treatment reduced the MT-stained area and TGF-β stained area in UUO kidneys (Ac, Bc). Aliskiren-treated TLR2-KO UUO kidneys showed a significant decrease in MT-stained and TGF-β stained areas compared with aliskiren-treated WT UUO kidneys (Ad, Bd). Aliskiren treatment reduced the renal mRNA expressions of TGF-β in UUO kidneys. Aliskiren-treated TLR2-KO UUO kidneys showed significant decreases in renal mRNA expression of TGF-β compared with aliskiren-treated WT UUO kidneys by RT-PCR (Bf). (C) Renin expression. The expression of renin was increased in UUO, A-UUO, and A-TRL2-KO UUO kidney (p < 0.05). (D) AT1R expression. (a) Sham-operated, (b) WT UUO, (c) aliskiren-treated WT UUO, (d) aliskiren-treated TLR2-KO UUO kidneys, (e) area of AT1R stain, (f) representative AT1R immunoblots: sham-operated (n = 3), WT-UUO (n = 3), A-UUO (n = 4), A-TLR2-KO-UUO (n = 4) (×200). The expression of AT1R was increased in UUO kidney. The area of AT1R stain in tubulointerstitium (yellow arrows). However, aliskiren treatment significantly decreased the AT1R expression in both WT UUO and TLR2-KO UUO kidneys compared with aliskiren-untreated WT UUO kidneys (Da-Dd and Df, p < 0.05). Although AT1R expression showed the increase tendency in aliskiren-treated TLR2-KO kidney compared with aliskiren-treated WT UUO kidney, there were no significant difference between two groups (p = 0.075). TLR, Toll-like receptor; UUO, unilateral ureteral obstruction; MT, Masson’s trichrome; TGF-β, transforming growth factor β; WT, wild type; KO, knockout; RT-PCR, real-time polymerase chain reaction; A-UUO, aliskiren-treated UUO WT mice (n = 8); A-TLR2-KO UUO, aliskiren-treated TLR2-KO UUO mice (n = 8); AT1R, angiotensin II type 1 receptor; S, sham-operated mice (n = 7); UUO, UUO operated mice (n = 8). ^a,b,cp < 0.05.